Nottingham, U.K., December 3rd, 2018
Quotient Sciences, a leading drug development services organization, has invested in additional spray drying capabilities at its formulation development and clinical trial manufacturing facility in Garnet Valley, PA.
In this latest U.S. expansion, Quotient has completed the installation of a GEA Niro Mobile Minor™ unit to support the rapid development of solid dispersions and clinical production of batches sizes up to 10 kg.
Over the past 20 years Quotient has built a strong reputation in addressing complex solubility and bioavailability challenges with a range of formulation technologies including spray drying, hot melt extrusion, lipidic systems and micronization. Small scale and pilot scale spray drying has been a core capability of Quotient’s portfolio of services in the U.K. and in 2017 the company established spray drying in the U.S. with the installation of a ProCepT spray dryer.
“Our investment in spray drying is in direct response to increasing client demand and the prevalence of poorly soluble molecules in their drug development pipelines,” said Mark Egerton, CEO of Quotient Sciences. “With spray drying expertise on both sides of the Atlantic, we’re now able to seamlessly support our global client base as they transition from preclinical to proof-of-concept patient trials.”
The 45,000-square foot Garnet Valley site is a hub for early phase formulation development and clinical trial manufacturing. The facility was designed to handle highly potent products with six high potency GMP manufacturing suites. Quotient expertise in handling high potent molecules encompasses more than 300 Category 3 - 5 compounds across its manufacturing sites.
Globally, Quotient has more than 800 employees across six operating sites in the U.K. and U.S., serving a global customer base of more than 150 biotech and pharma clients.